´ëÇÑ°íÇ÷¾ÐÇÐȸ Á¦55ȸ Ãß°è±¹Á¦Çмú´ëȸ (2ÀÏÂ÷) : 2021-11-06 |
|
´ëÇÑ°íÇ÷¾ÐÇÐȸ Á¦55ȸ Ãß°è±¹Á¦Çмú´ëȸ (2ÀÏÂ÷) : 2021-11-06 ±³À°ÀÏÀÚ : 2021-11-06 ±³À°Àå¼Ò : ¼¿ï ÄÜ·¡µå È£ÅÚ ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ-¿ÀÇÁ¶óÀÎ º´Çà) Á¦55ȸ Ãß°è±¹Á¦Çмú´ëȸ (2ÀÏÂ÷) ÁÖÃÖ±â°ü : ´ëÇÑ°íÇ÷¾ÐÇÐȸ ´ã´çÀÚ : ±èÈñÁÖ ¿¬¶ôó : 02-565-3350 À̸ÞÀÏ : ksh@koreanhypertension.org ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, ½Å°æ°ú, °¡Á¤ÀÇÇаú»ý¸®ÇÐ, ¾à¸®ÇÐ, ÀÇ·áÀ±¸®ÇÐ, ÀÇ·áÄ¿¹Â´ÏÄÉÀ̼Ç, ÀÇÇб³À°, Âü¼®¿¹»óÀοø : 800¸í Èñ¸ÁÆòÁ¡ : 6Á¡ Áö¿ª : ¼¿ïƯº°½Ã ±³À°½Ã°£ : 29 ½Ã°£ 50ºÐ ¼¼ºÎ¼ö°·á : 80,000¿ø ºñ°í *µî·Ïºñ : »çÀüµî·Ï-±³¼ö ¹× Àü¹®ÀÇ Á¤È¸¿ø(6¸¸¿ø), Á¤È¸¿ø ¿Ü(8¸¸¿ø) / Àü°øÀÇ ¹× ±âŸ(4¸¸¿ø) / °£È£»ç,¿µ¾ç»ç, ¾à»ç(2¸¸¿ø) / 65¼¼ ÀÌ»ó Á¤È¸¿ø&Çлý(¹«·á) *ÇöÀåµî·ÏÀº ¾øÀ½ ±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ ±³À°½Ã°£ 11-06 Rooom A 08:00~08:50 Industrial Breakfast Symposium I ÀÌÀç¿ì(ÃáÇغ´¿ø) ±³À°½Ã°£ 11-06 Rooom B 08:00~08:50 Industrial Breakfast Symposium II À̹æÇå(ÇѾçÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom C 08:00~08:20 The importance of TG((TriGlyceride) management and a review of clinical trial of Fenofibrate choline ¹Ú¸í¼ö(ÇѸ²ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom C 08:20~08:40 The Benefit of SPC(Single Pill Combinations) for Hypertensive patients with Dyslipidemia ¼ÕÀϼ®(°æÈñÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom D 08:00~08:50 Industrial Breakfast Symposium IV À¯¼®Èñ(LSK Global PS) ±³À°½Ã°£ 11-06 Rooom A 09:00~09:15 Blood pressure lowering effect of SGLT2(Sodium Glucose Co-Transporter 2) inhibitor and HF(Heart Failure) ¿ÀÀç¿ø(¿¬¼¼ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom A 09:15~09:30 Ambulatory blood pressure monitoring in HFrEF(Heart Failure with Reduced Ejection Fraction): Can it be a predictor of worsening? Takahiro Komori(Japan) ±³À°½Ã°£ 11-06 Rooom A 09:30~09:45 Hypertension treatment in HFpEF(Heart Failure with Preserved Ejection Fraction) ¹Ú¼ºÇÏ(¿¬¼¼ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom A 09:45~10:00 Visit-to-visit blood pressure variability and HF(Heart Failure) ÀÌÁÖÈñ(ÃæºÏÀÇ´ë) Åä·Ð 11-06 Rooom A 10:00~10:15 ÆгΠÅäÀÇ À̼±±â, ½ÅÁ¤ÈÆ, ±èºÀÁØ(ÇѸ²ÀÇ´ë, ÇѾçÀÇ´ë, °í½ÅÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom B 09:00~09:15 Blood pressure variability and atrial fibrillation À̼ҷÉ(¼¿ïÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom B 09:15~09:30 Blood pressure variability and white coat and masked hypertension ±è¼ÛÀÌ(Á¦ÁÖÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom B 09:30~09:45 Blood pressure variability and nighttime and early morning blood pressure pattern ¹Ú»ó¹Î(À»ÁöÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom B 09:45~10:00 Blood pressure variability and its therapeutic implication ±èÇý¹Ì(Áß¾ÓÀÇ´ë) Åä·Ð 11-06 Rooom B 10:00~10:15 ÆгΠÅäÀÇ ¹Ú»óÇö, ±è¹Ì³ª, ±èÀ̽Ä, ÀÌÀº¹Ì(À»ÁöÀÇ´ë, °í·ÁÀÇ´ë, ÀüºÏÀÇ´ë, ¿ø±¤ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom C 09:00~09:15 Associations between pregnancy hypertensive disorders and common cardiovascular disorders: The CALIBER(Cardiovascular Research using Linked Bespoke Studies and Electronic Health Records) study ¼³»óÈÆ(ÀÎÁ¦ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom C 09:15~09:30 An update on the pathophysiology of preeclampsia Á¶ÀÎÁ¤(ÀÌÈÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom C 09:30~09:45 Threshold and target blood pressure for drug therapy in gestational hypertension ¹ÚÀçÇü(Ãæ³²ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom C 09:45~10:00 How to guide and manange postnatal hypertensive women ±èÁ¤¼ö(ºÎ»êÀÇ´ë) Åä·Ð 11-06 Rooom C 10:00~10:15 ÆгΠÅäÀÇ ÀÌ»óÇö, ÀÓ°æÈñ, ±èÇüÀ±(ºÎ»êÀÇ´ë, µ¿¾ÆÀÇ´ë, Àü³²ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom D 09:00~09:15 How to use home blood pressure monitors in clinical practice ±èÀÎö(°è¸íÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom D 09:15~09:30 Nocturnal hypertension and role of home blood pressure monitoring ·ùµ¿¿(°¿øÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom D 09:30~09:45 Methodological issues in home blood pressure monitoring ½ÅÁøÈ£(ÇѾçÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom D 09:45~10:00 Wearable devices and telemonitoring ÀÌÂùÁÖ(¿¬¼¼ÀÇ´ë) Åä·Ð 11-06 Rooom D 10:00~10:15 ÆгΠÅäÀÇ ÀÌÁÖÈñ, Á¶µ¿Çõ, Á¶À翵(ÃæºÏÀÇ´ë, ¿¬¼¼¿øÁÖÀÇ´ë, Àü³²ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom A 10:25~11:00 Recent Progress and Future Perspective of Hypertension Research Youngsuk Oh(USA) ±³À°½Ã°£ 11-06 Rooom A 11:10~11:40 Industrial Symposium I Æí¿í¹ü(ÀÌÈÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom B 11:10~11:25 Journey of Valsartan to Provide CV(Cardiovascula) Protection for Patients at risk ¹ÚÁغó(¼¿ïÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom B 11:25~11:40 Earliest start of essential treatment & Latest finish in patient journey of HFrEF(Heart Failure with Reduced Ejection Fraction) ÀÌÂùÁÖ(¿¬¼¼ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom C 11:10~11:40 Maximizing benefits in hypertension management with Perindopril and Indapamide ±èÀÎö(°è¸íÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom D 11:10~11:25 New LDL-C(Low-Density Lipoprotein Cholesterol) Guidelines on Very High-risk Group : The Lower, The Better! ±èÇöÁø(ÇѾçÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom D 11:25~11:40 ¡®Higher Risk, Higher Benefit¡¯ Strategy with Evolocumab in Post-MI(Myocardial Infarction) ÀÌÂùÁÖ(¿¬¼¼ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom A 11:50~12:25 Young Investigator Award ±è±ÙÈ£, ÀÓ»óÇö(ÇѾçÀÇ´ë, °¡Å縯ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom B 11:50~12:25 Industrial Symposium V ¼ÕÀϼ®(°æÈñÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom C 11:50~12:25 Industrial Symposium VII ±è¹®Àç(¼øõÀÇ·áÀç´Ü) ±³À°½Ã°£ 11-06 Rooom A 12:35~13:20 Luncheon Symposium IV ±èÁ¾Áø(Â÷ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom B 12:35~13:00 The role of s-amlodipine in elderly hypertensive patients ¹Ú»ó¹Î(À»ÁöÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom C 12:35~12:55 The Recent Trend of Simultaneous Management of Hypertension and Dyslipidemia ÁÖÇüÁØ(°í·ÁÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom C 12:55~13:15 Combination therapy of antihypertensive drugs for CV(Cardiovascula) protection Á¤Çý¹®(°æÈñÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom A 13:30~13:45 Assessment of psychologic problem in elderly hypertensive patients ½Åö¹Î(°í·ÁÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom A 13:45~14:00 Resistant hypertension in elderly ¹Ú¼ºÇÏ(¿¬¼¼ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom A 14:00~14:15 Role of ABPM(Ambulatory Blood Pressure Monitoring) in elderly hypertensive patients Miguel Camafort-Babkowski(Spain) ±³À°½Ã°£ 11-06 Rooom A 14:15~14:30 Achieving target blood pressure in older adults: Beyond the guidelines ±è±¤ÀÏ(¼¿ïÀÇ´ë) Åä·Ð 11-06 Rooom A 14:30~14:45 ÆгΠÅäÀÇ ÀÌÇØ¿µ, Ȳ°æ±¹, ±èÇзÉ(¼¿ïÀÇ´ë, ÃæºÏÀÇ´ë, ¼¿ïÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom B 13:30~13:45 Mechanisms of the effects of Gut Microbiome ¿ÀÁø°æ(Ãæ³²ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom B 13:45~14:00 Gut Microbiota in Hypertension Á¶Á¤¼±(°¡Å縯ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom B 14:00~14:15 Gut Microbiome in Korean Patients ±èÇüÀ±(Àü³²ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom B 14:15~14:30 Fecal Microbiota Transplantation ±ÇűÙ(°¡Å縯ÀÇ´ë) Åä·Ð 11-06 Rooom B 14:30~14:45 ÆгΠÅäÀÇ ¹ÚÂù¼®, Á¶À翵, Çã¶õ(°¡Å縯ÀÇ´ë, Àü³²ÀÇ´ë, ÇѾçÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom C 13:30~13:45 Introduction of Sedentary behavior and health ÀÓÁ¤ÁØ(¼¿ï´ëÇб³) ±³À°½Ã°£ 11-06 Rooom C 13:45~14:00 Sedentary behavior and metabolic disease ¹Ú¼öÇö(Çѱ¹½ºÆ÷Ã÷Á¤Ã¥°³¹ß¿ø) ±³À°½Ã°£ 11-06 Rooom C 14:00~14:15 Sedentary behavior and CVD(Cardiovascular Disease) ±è¿ëȯ(°¸ª¿øÁÖ´ëÇб³) ±³À°½Ã°£ 11-06 Rooom C 14:15~14:30 Çѱ¹ÀÎÀÇ Sedentary behavior ÇöȲ°ú °³¼± Àü·« ¹ÚÇöÅÂ(µ¿¾Æ´ëÇб³) Åä·Ð 11-06 Rooom C 14:30~14:45 ÆгΠÅäÀÇ ÀÌ¿Â, À̽¿±, °ÇöÁÖ(Çѱ¹½ºÆ÷Ã÷Á¤Ã¥°úÇпø, °¡Å縯°üµ¿´ëÇб³, ¼øõÇâ´ëÇб³) ±³À°½Ã°£ 11-06 Rooom D 13:30~13:45 Overview of Biomarker in Hypertension ÃÖ¼®¿ø(Áß¾Óº¸Èƺ´¿ø) ±³À°½Ã°£ 11-06 Rooom D 13:45~14:00 Biomarker of Vascular Damage Á¶µ¿Çõ(¿¬¼¼¿øÁÖÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom D 14:00~14:15 Biomarker of Renal Damage ±è¿ìÇö(ÇѾçÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom D 14:15~14:30 Biomarker of Cardiac Damage Á¤¹ÌÇâ(ÇѸ²ÀÇ´ë) Åä·Ð 11-06 Rooom D 14:30~14:45 ÆгΠÅäÀÇ ±èÀÀÁÖ, ½Å¹Ì½Â, ÃÖ¼ºÈÆ, ÇѼº¿ì(°í·ÁÀÇ´ë, °¡ÃµÀÇ´ë, ÇѸ²ÀÇ´ë, ÇѸ²ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom A 14:55~15:10 Controversy on the reproducibility of ABPM(Ambulatory Blood Pressure Monitoring) parameters Á¤ÀÎÇö(¿¬¼¼ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom A 15:10~15:25 Comparison among Auscultatory, Tonometry and Oscillometric Methods for ABPM(Ambulatory Blood Pressure Monitoring) ¹Ú»ó¹Î(À»ÁöÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom A 15:25~15:40 Three Methods to Evaluate Nocturnal Blood Pressure Takayoshi Ohkubo(Japan) ±³À°½Ã°£ 11-06 Rooom A 15:40~15:55 Drug Therapy to Reduce Ambulatory Central Blood Pressure Ȳ¿ø¹Î(°Ç¾çÀÇ´ë) Åä·Ð 11-06 Rooom A 15:55~16:10 ÆгΠÅäÀÇ °½ÃÇõ, ±èÇзÉ, Á¶Á¤¼±(¼¿ïÀÇ´ë, ¼¿ïÀÇ´ë, °¡Å縯ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom B 14:55~15:10 Epidemiology of resistant hypertension: global perspective & Korean ¹ÚÁøÁÖ(¼¿ïÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom B 15:10~15:25 Updates in sleep apnea in patients with hypertension ÃÖÀÚ¿¬(°í·ÁÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom B 15:25~15:40 Differential diagnosis of endocrine hypertension ±èÁ¤Èñ(¼¿ïÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom B 15:40~15:55 The current status of devices for the treatment of resistant hypertension Á¶Áø¸¸(°æÈñÀÇ´ë) Åä·Ð 11-06 Rooom B 15:55~16:10 ÆгΠÅäÀÇ ¹®À翬, ÃÖÀçÇõ, ÃÖö¿õ(Â÷ÀÇ´ë, ÇѸ²ÀÇ´ë, °í·ÁÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom C 14:55~15:10 Insufficient sleep and blood pressure ±è´ë¿µ(Ãæ³²ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom C 15:10~15:25 Insomnia and blood pressure ¼ÛÆĸá¶ó(ÀÎÁ¦ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom C 15:25~15:40 Sleep-Disordered Breathing and blood pressure º¯Á¤ÀÍ(°æÈñÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom C 15:40~15:55 Impact of hypoxia during sleep on neurological outcome among stroke patients ±èÄ¡°æ(°í·ÁÀÇ´ë) Åä·Ð 11-06 Rooom C 15:55~16:10 ÆгΠÅäÀÇ ÇѼöÇö, ¹Ú¹«¼®, ±è¿¹¸²(Áß¾ÓÀÇ´ë, ÀÌÈÀÇ´ë, ÇѸ²ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom D 15:35~15:55 °í·É °íÇ÷¾ÐÀÇ Áø´Ü°ú ÃʱâÄ¡·á ÃÖ¼ºÈÆ(ÇѸ²ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom D 15:55~16:15 ÀþÀº °íÇ÷¾ÐÀÇ Áø´Ü°ú ÃʱâÄ¡·á ³ªÁø¿À(°í·ÁÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom D 16:15~16:35 °íÇ÷¾Ð ¾àÁ¦ÀÇ ´Ü°èÀû Áõ·®¹æ¹ý ±èÁÖÇÑ(Àü³²ÀÇ´ë) Åä·Ð 11-06 Rooom D 16:35~16:50 ÆгΠÅäÀÇ ½ÅÁøÈ£, ÀÌÇØ¿µ, Á¤¿íÁø(ÇѾçÀÇ´ë, ¼¿ïÀÇ´ë, °¡ÃµÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom A 16:20~16:50 Brain renin angiotensin system in the management of hypertension and heart failure Catherine Llorens-Cortes(France) ±³À°½Ã°£ 11-06 Rooom A 17:00~17:15 Mechanisms of Relation of Dietary salt to Blood Pressure ÃÖÈ«»ó(Àü³²ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom A 17:15~17:30 Who are Salt sensitive? (diagnosis and risk factor) À̹«¿ë(µ¿±¹ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom A 17:30~17:45 Methodologically robust or flawed studies in salt and hypertension Á¤¹ÌÇâ(ÇѸ²ÀÇ´ë) Åä·Ð 11-06 Rooom A 17:45~18:00 Tissue sodium excess: nature and implications for hypertension Giacomo Rossitto(Italy) Åä·Ð 11-06 Rooom A 18:00~18:15 ÆгΠÅäÀÇ À̱Լ·, ¿ÀÁø°æ, ÁøÁ¤¿¬(°¡Å縯ÀÇ´ë, Ãæ³²ÀÇ´ë, À»ÁöÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom B 17:00~17:15 Air pollution, hypertension and cardiovascular disease ¹Ú»ó¹Î(¼¿ï´ëÇб³) ±³À°½Ã°£ 11-06 Rooom B 17:15~17:30 Noise pollution and hypertension À¯ÁøÇÏ(¿¬¼¼ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom B 17:30~17:45 Occupational stressors and hypertension °¸ð¿(°¡Å縯ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom B 17:45~18:00 Temperature and hypertension - Àü°æÇö(Àϻ꺴¿ø) Åä·Ð 11-06 Rooom B 18:00~18:15 ÆгΠÅäÀÇ ±èÈ¿Àº, ¼Áö¿ø, Á¤Çý¹®, Çã¶õ(¿¬¼¼ÀÇ´ë, ¿¬¼¼ÀÇ´ë, °æÈñÀÇ´ë, ÇѾçÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom B 17:00~17:20 Pros Á¶»óÈ£(ÇѸ²ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom B 17:20~17:40 Cons ¹Ú»ó¹Î(À»ÁöÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom B 17:40~17:45 Pros(rebuttal) Á¶»óÈ£(ÇѸ²ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom B 17:45~17:50 Cons(rebuttal) ¹Ú»ó¹Î(À»ÁöÀÇ´ë) Åä·Ð 11-06 Rooom B 17:50~18:15 ÆгΠÅäÀÇ ±èÁöÈñ, Á¶Á¤¼±, ȲÈñÁ¤(°¡Å縯ÀÇ´ë, °¡Å縯ÀÇ´ë, °æÈñÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom B 17:00~17:20 °íÇ÷¾Ð ¾àÁ¦º¹¿ë ½Ã°£. ¾Æħ vs. Ãëħ Àü À¯½Â±â(À»ÁöÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom B 17:20~17:40 º¯µ¿ÀÌ ½ÉÇÑ °íÇ÷¾Ð ȯÀÚÀÇ Ä¡·á Á¤ÁßÈ(Á¶¼±ÀÇ´ë) ±³À°½Ã°£ 11-06 Rooom B 17:40~18:00 ¸¸¼º ÄáÆϺ´À» µ¿¹ÝÇÑ °íÇ÷¾Ð ȯÀÚÀÇ ½ÄÀÌ¿ä¹ý°ú ¾à¹°Ä¡·á ¼ÕÀϼ®(°æÈñÀÇ´ë) Åä·Ð 11-06 Rooom B 18:00~18:15 ÆгΠÅäÀÇ Á¶ÀºÁÖ, ±è±¤ÀÏ, ±è´ëÈñ(°¡Å縯ÀÇ´ë, ¼¿ïÀÇ´ë, ¿ï»êÀÇ´ë) |
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|